Kirsten A Porter-Stransky1, Samuel W Centanni2, Saumya L Karne1, Lindsay M Odil3, Sinda Fekir3, Jennifer C Wong1, Canaan Jerome1, Heather A Mitchell1, Andrew Escayg1, Nigel P Pedersen4, Danny G Winder2, Darlene A Mitrano5, David Weinshenker6. 1. Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia. 2. Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee; Vanderbilt Center for Addiction Research, Vanderbilt University School of Medicine, Nashville, Tennessee. 3. Program in Neuroscience, Christopher Newport University, Newport News, Virginia. 4. Department of Neurology, Emory University School of Medicine, Atlanta, Georgia. 5. Program in Neuroscience, Christopher Newport University, Newport News, Virginia; Department of Molecular Biology and Chemistry, Christopher Newport University, Newport News, Virginia. 6. Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia. Electronic address: dweinsh@emory.edu.
Abstract
BACKGROUND: Dysregulation of arousal is symptomatic of numerous psychiatric disorders. Previous research has shown that the activity of dopamine (DA) neurons in the ventral periaqueductal gray (vPAG) tracks with arousal state, and lesions of vPAGDA cells increase sleep. However, the circuitry controlling these wake-promoting DA neurons is unknown. METHODS: This study combined designer receptors exclusively activated by designer drugs (DREADDs), behavioral pharmacology, electrophysiology, and immunoelectron microscopy in male and female mice to elucidate mechanisms in the vPAG that promote arousal. RESULTS: Activation of locus coeruleus projections to the vPAG or vPAGDA neurons induced by DREADDs promoted arousal. Similarly, agonist stimulation of vPAG alpha1-adrenergic receptors (α1ARs) increased latency to fall asleep, whereas α1AR blockade had the opposite effect. α1AR stimulation drove vPAGDA activity in a glutamate-dependent, action potential-independent manner. Compared with other dopaminergic brain regions, α1ARs were enriched on astrocytes in the vPAG, and mimicking α1AR transmission specifically in vPAG astrocytes via Gq-DREADDS was sufficient to increase arousal. In general, the wake-promoting effects observed were not accompanied by hyperactivity. CONCLUSIONS: These experiments revealed that vPAG α1ARs increase arousal, promote glutamatergic input onto vPAGDA neurons, and are abundantly expressed on astrocytes. Activation of locus coeruleus inputs, vPAG astrocytes, or vPAGDA neurons increase sleep latency but do not produce hyperactivity. Together, these results support an arousal circuit whereby noradrenergic transmission at astrocytic α1ARs activates wake-promoting vPAGDA neurons via glutamate transmission.
BACKGROUND: Dysregulation of arousal is symptomatic of numerous psychiatric disorders. Previous research has shown that the activity of dopamine (DA) neurons in the ventral periaqueductal gray (vPAG) tracks with arousal state, and lesions of vPAGDA cells increase sleep. However, the circuitry controlling these wake-promoting DA neurons is unknown. METHODS: This study combined designer receptors exclusively activated by designer drugs (DREADDs), behavioral pharmacology, electrophysiology, and immunoelectron microscopy in male and female mice to elucidate mechanisms in the vPAG that promote arousal. RESULTS: Activation of locus coeruleus projections to the vPAG or vPAGDA neurons induced by DREADDs promoted arousal. Similarly, agonist stimulation of vPAG alpha1-adrenergic receptors (α1ARs) increased latency to fall asleep, whereas α1AR blockade had the opposite effect. α1AR stimulation drove vPAGDA activity in a glutamate-dependent, action potential-independent manner. Compared with other dopaminergic brain regions, α1ARs were enriched on astrocytes in the vPAG, and mimicking α1AR transmission specifically in vPAG astrocytes via Gq-DREADDS was sufficient to increase arousal. In general, the wake-promoting effects observed were not accompanied by hyperactivity. CONCLUSIONS: These experiments revealed that vPAG α1ARs increase arousal, promote glutamatergic input onto vPAGDA neurons, and are abundantly expressed on astrocytes. Activation of locus coeruleus inputs, vPAG astrocytes, or vPAGDA neurons increase sleep latency but do not produce hyperactivity. Together, these results support an arousal circuit whereby noradrenergic transmission at astrocytic α1ARs activates wake-promoting vPAGDA neurons via glutamate transmission.
Authors: Jan Willem de Gee; Olympia Colizoli; Niels A Kloosterman; Tomas Knapen; Sander Nieuwenhuis; Tobias H Donner Journal: Elife Date: 2017-04-11 Impact factor: 8.140
Authors: Kathryn J Reissner; Robyn M Brown; Sade Spencer; Phuong K Tran; Charles A Thomas; Peter W Kalivas Journal: Neuropsychopharmacology Date: 2013-08-29 Impact factor: 7.853
Authors: Matthew E Carter; Ofer Yizhar; Sachiko Chikahisa; Hieu Nguyen; Antoine Adamantidis; Seiji Nishino; Karl Deisseroth; Luis de Lecea Journal: Nat Neurosci Date: 2010-10-31 Impact factor: 24.884
Authors: Stephen V Mahler; Elena M Vazey; Jacob T Beckley; Colby R Keistler; Ellen M McGlinchey; Jennifer Kaufling; Steven P Wilson; Karl Deisseroth; John J Woodward; Gary Aston-Jones Journal: Nat Neurosci Date: 2014-03-02 Impact factor: 24.884
Authors: Kirsten A Porter-Stransky; Alyssa K Petko; Saumya L Karne; L Cameron Liles; Nikhil M Urs; Marc G Caron; Carlos A Paladini; David Weinshenker Journal: Addict Biol Date: 2019-08-23 Impact factor: 4.280
Authors: Michael A Kelberman; Claire R Anderson; Eli Chlan; Jacki M Rorabaugh; Katharine E McCann; David Weinshenker Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.472
Authors: Kerry J Ressler; Sabina Berretta; Vadim Y Bolshakov; Isabelle M Rosso; Edward G Meloni; Scott L Rauch; William A Carlezon Journal: Nat Rev Neurol Date: 2022-03-29 Impact factor: 44.711
Authors: Laura M Butkovich; Madelyn C Houser; Termpanit Chalermpalanupap; Kirsten A Porter-Stransky; Alexa F Iannitelli; Jake S Boles; Grace M Lloyd; Alexandra S Coomes; Lori N Eidson; Maria Elizabeth De Sousa Rodrigues; Danielle L Oliver; Sean D Kelly; Jianjun Chang; Nora Bengoa-Vergniory; Richard Wade-Martins; Benoit I Giasson; Valerie Joers; David Weinshenker; Malú Gámez Tansey Journal: J Neurosci Date: 2020-08-31 Impact factor: 6.167
Authors: Gina R Poe; Stephen Foote; Oxana Eschenko; Joshua P Johansen; Sebastien Bouret; Gary Aston-Jones; Carolyn W Harley; Denise Manahan-Vaughan; David Weinshenker; Rita Valentino; Craig Berridge; Daniel J Chandler; Barry Waterhouse; Susan J Sara Journal: Nat Rev Neurosci Date: 2020-09-17 Impact factor: 34.870
Authors: Daniel Lustberg; Alexa F Iannitelli; Rachel P Tillage; Molly Pruitt; L Cameron Liles; David Weinshenker Journal: Psychopharmacology (Berl) Date: 2020-04-20 Impact factor: 4.530
Authors: Stephanie L Foster; Daniel J Lustberg; Nicholas H Harbin; Sara N Bramlett; John R Hepler; David Weinshenker Journal: Psychopharmacology (Berl) Date: 2021-06-29 Impact factor: 4.415